Contineum Therapeutics, Inc. Class A Common Stock
$12.38
+0.81%Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.3).
Valuation inputs: P/E -5.3, earnings yield N/A, momentum +0.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -23.0%, ROIC -25.3%).
Profitability stack: net margin 0.0%, ROE -23.0%, ROIC -25.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +5.7%, momentum +0.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Contineum Therapeutics, Inc. Class A Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Contineum Therapeutics, Inc. Class A Common Stock Fair Value Envelope
Contineum Therapeutics, Inc. Class A Common Stock Profit Bridge
Profitability Analysis
Contineum Therapeutics, Inc. Class A Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Contineum Therapeutics, Inc. Class A Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Contineum Therapeutics, Inc. Class A Common Stock Street Expectations Map
Wall Street analysts project that CTNM stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 16.00, with estimates ranging from a low of 16.00 to a high of 16.00.
The consensus 1-year price target stands at 16.00, with estimates ranging from a low of 16.00 to a high of 16.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Contineum Therapeutics, Inc. Class A Common Stock Insider Positioning
During the last 12 months, insiders have purchased $414K and sold $753K worth of CTNM shares, resulting in $339K of net selling activity.
3 Months
0
0.00
12.2K
161.42K
-161K
-$161K
3-6 Months
0
0.00
41.2K
591.55K
-592K
-$592K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
103.3K
414.03K
0
0.00
+414K
+$414K
Top Buyers
Boyce Sarah
Director
$59K
Brady Todd R.
Director
$59K
Ignelzi Troy A.
Director
$59K
Lyons-Williams Lori
Director
$59K
Ware Olivia C
Director
$59K
Top Sellers
Lorrain Daniel S.
Officer: Chief Scientific Officer
$496K
Watkins Tim
Officer: Cmo & Head Of Development
$137K
Stengone Carmine N.
Director, Officer: Ceo And President
$120K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $339K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
No Dividend Yield Data
CTNM has not reported any dividend yield values in the available annual periods.
ctnm Dividend History
Learning Layer
Related Guides
Build conviction on CTNM by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.